TYK2 and psoriasis: The effect is similar as the most advanced clinical TYK2 pseudokinase ligand Deucravacitinib and more potent than the TYK2 kinase inhibitor that entered Phase II clinical development against moderate-to-severe psoriasis, Ropsacitinib (Supplementary Figure 7; Figures 4C).